AI-POWERED GENOMIC SIGNAL DETECTION
Multi-Omics Methylation Blood Biopsy for Early Cancer Detection
Licensing-Ready Clinical Evidence Package
What Investors, Partners & Customers Receive
The Complete Evidence Package
Delivered to Investors, Partners, and Customers
A single curated set of materials supporting diligence, licensing, and commercialization decisions.
01 Clinical Data Collection
Locked database, complete annotations, protocol adherence
02 Independent Lab QC
CLIA/CAP-aligned records, batch logs, deviation reports
03 Performance Metrics
Sensitivity & specificity with confidence intervals + AUC
04 Subgroup Analyses
Stage- and geography-specific results where powered
05 Independent Validation
Third-party statistical report on locked analysis set
06 Scientific Publication
Manuscript submission and supporting materials
KEY TAKEAWAY:
One package serves investors, pharma/diagnostics partners, and commercial customers.
Clinical Foundation
Sample Collection, Data Integrity & Laboratory QC
Clinical Foundation
Sample Collection, Data Integrity & Laboratory QC
Complete Blood Sample Collection
- Full intended-use cohort enrolled
- Source-document verified clinical database
- Demographics, risk factors, and staging complete
Independent Laboratory QC
- CLIA/CAP or equivalent certification
- Batch records and reagent lot tracking
- Instrument calibration and QC acceptance criteria
- Deviation and corrective-action documentation
KEY TAKEAWAY:
Partners receive audit-ready evidence that the data were generated under controlled conditions.
Clinical Performance Metrics
Sensitivity, Specificity & Confidence Intervals
Primary endpoints calculated on the locked analysis set with pre-specified statistical methods.
Sensitivity
True-positive rate by cancer type and overall, with Wilson or Clopper-Pearson CIs
Specificity
True-negative rate in the intended-use population with confidence intervals
ROC / AUC
Full receiver-operating-characteristic analysis supporting the risk score
Stage Stratification
Performance by stage (I–IV) where adequately powered
KEY TAKEAWAY:
Transparent performance numbers with confidence intervals enable independent partner assessment.
Subgroup Analyses & Independent Validation
Consistency and Third-Party Confirmation
Cancer-Stage Analyses
Stage-specific sensitivity where sample size supports reliable estimates. Forest-plot style summaries of consistency across stages.
Geographic & Demographic Subgroups
Performance evaluated across relevant geographies and demographic strata when adequately powered.
Independent Clinical Validation Report
Formal report from an independent biostatistician or CRO. Analysis plan locked prior to unblinding. Full statistical methods, results, and limitations included.
KEY TAKEAWAY:
Independent validation reduces partner risk and accelerates diligence.
Scientific Publication
Peer-Reviewed Evidence for Stakeholders
A manuscript describing study design, assay methodology, and clinical performance submitted to a relevant journal.
- Target journals appropriate for liquid-biopsy and early-detection research
- Full methods, results, and supplemental materials
- Manuscript available under embargo or upon acceptance for partner review
- Supports scientific credibility with both investors and commercial customers
KEY TAKEAWAY:
Publication provides transparent, citable evidence for all stakeholder groups.
Analytical Validity Package
Essential for Pharmaceutical & Diagnostics Partners
Assay Reproducibility
Intra- and inter-assay precision across operators, instruments, reagent lots, and days. CVs for biomarkers and composite risk score.
Analytical Validity
Limit of detection, limit of blank, analytical specificity, interfering substances, reportable range, and linearity.
Sample Stability
Stability data under ambient, refrigerated, and frozen conditions, including freeze-thaw cycles and shipping profiles.
Chain of Custody
Unique identifiers, shipping manifests, receipt logs, and storage records documenting sample integrity from collection to analysis.
KEY TAKEAWAY:
These data de-risk manufacturing, regulatory, and commercial transfer for partners.
Intellectual Property Documentation
Clear Ownership and Freedom to Operate
01. Issued patents and pending applications covering assay, biomarkers, and analysis methods
02. Invention disclosures and assignment records from inventors
03. Employee and consultant agreements with IP assignment clauses
04. Freedom-to-operate opinion or landscape analysis (as available)
05. Clear chain of title supporting licensing discussions
KEY TAKEAWAY:
Clean IP documentation is a standard prerequisite for pharmaceutical and diagnostics licensing.
Secure Data Room
Controlled Access for Diligence
A virtual data room containing the complete licensing-ready package with audit logging.
- Clinical study report & statistical analysis plan
- Analytical validity and reproducibility packages
- Intellectual property documentation
- De-identified datasets (or controlled summary access)
- Independent validation report
- Sample stability & chain-of-custody records
- Manuscript and publication materials
- Quality-system and laboratory certification files
KEY TAKEAWAY:
Partners receive structured, auditable access rather than ad-hoc document exchange.
Value to Each Audience
Investors • Partners • Customers
Investors
- De-risked clinical claims
- Clear path to licensing revenue
- Publication credibility
- IP position for valuation
Pharma / Diagnostics Partners
- Analytical validity for tech transfer
- Reproducibility & stability data
- Independent validation
- Ready-to-license package
Customers / Clinicians
- Published performance data
- Transparent confidence intervals
- Stage-specific results
- Scientific backing for adoption
KEY TAKEAWAY:
The same evidence package speaks to capital, strategic partners, and end users.
Deliverables Checklist
Licensing-Ready Package Contents
- Complete blood sample and clinical data collection
- Independent laboratory quality-control documentation
- Sensitivity and specificity with confidence intervals
- Cancer-stage and geographic subgroup analyses
- Independent clinical validation report
- Scientific publication submission
- Assay reproducibility data
- Analytical validity studies
- Sample stability and chain-of-custody records
- Intellectual property documentation
- Secure data room access
KEY TAKEAWAY:
All items required for a complete partner diligence package are enumerated.